

Product	Mechanism	Indication	Phase 1	Phase 2	Phase 3	Countries Where Registered
Zanubrutinib	BTK inhibitor	CLL/SLL				US, EU (CLL), and several ex-EU/US countries
		WM				US, EU, and several ex-EU/US countries
		R/R FL				US, EU, and several ex-EU/US countries
		R/R MZL				US, EU, and several ex-EU/US countries
		TN MCL				
		R/R MCL				US and some ex-US countries
		R/R DLBCL with CD79B				
		Previously treated B-cell malignancies				
Sonrotoclax	BCL2 inhibitor	TN CLL ^a				
		R/R WM				
		R/R CLL				
		R/R MCL				
		R/R MM with t(11;14)				
		AML/MDS				
		B-cell malignancies				

Safety and efficacy have not been established for investigational products and/or uses.

Abbreviations: AML, acute myeloid leukemia; BCL2, B-cell lymphoma 2; BTK, Bruton tyrosine kinase; CD79B, cluster of differentiation 79B; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; MDS, myelodysplastic syndromes; MM, multiple myeloma; MZL, marginal zone lymphoma; R/R, recurrent/refractory; SLL, small lymphocytic lymphoma; TN, treatment naive; WM, Waldenström macroglobulinemia.

^aIn combination with zanubrutinib.

Product	Mechanism	Indication	Phase 1	Phase 2	Phase 3	Countries Where Registered
BGB-16673	BTK-targeted CDAC	B-cell malignancies				
		R/R MCL and R/R CLL				
BGB-21447	next gen BCL2 inhibitor	B-cell malignancies				
Tislelizumab	anti-PD-1	R/R cHL				China
Ociperlimab	anti-TIGIT	R/R DLBCL				
Zanubrutinib	BTK inhibitor	Primary membranous nephropathy				
		Lupus nephritis				
BGB-45035	IRAK4-targeted CDAC	Immunology & inflammation				
Blinatumomab ¹	CD3 X CD19	Pediatric R/R BP-ALL				

Safety and efficacy have not been established for investigational products and/or uses.

Abbreviations: BCL2, B-cell lymphoma 2; BP-ALL, B-cell precursor acute lymphoblastic leukemia; BTK, Bruton tyrosine kinase; CD3, cluster of differentiation 3; CD19, cluster of differentiation 19; CDAC, chimeric degradation activating compound; cHL, classical Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; IRAK4, interleukin-1 receptor-associated kinase 4; MCL, mantle cell lymphoma; PD-1, programmed cell death protein 1; R/R, recurrent/refractory; TIGIT, T-cell immunoreceptor with Ig and ITIM domains.

¹Amgen collaboration; BeiGene has China commercial rights.

Product	Mechanism	Indication	Phase 1	Phase 2	Phase 3	Countries Where Registered
Tislelizumab	anti-PD-1	1L NonSq NSCLC				EU and some ex-EU countries
		1L Sq NSCLC				EU and some ex-EU countries
		2/3L NSCLC				EU and some ex-EU countries
		Neo/adj NSCLC				
		1L ES-SCLC				China
		1L ESCC				China
		2L ESCC				US, EU, and some ex-US, ex-EU countries
		LA ESCC				
		1L GC/GEJC				China
		1L NPC				China
		1L HCC				China
		1L UBC				
		2/3L HCC				China
		1L NSCLC (subcutaneous formulation)				
Ociperlimab	anti-TIGIT	1L PD-L1 high NSCLC				
		NSCLC dose confirmation				
BG-68501 ¹	CDK2 inhibitor	BC and solid tumors				

Safety and efficacy have not been established for investigational products and/or uses.

Abbreviations: 1L, first line; 2L, second line; 3L, third line; BC, breast cancer; CDK2, cyclin-dependent kinase 2; ESCC, esophageal squamous cell carcinoma; ES-SCLC, extensive-stage small cell lung cancer; GC, gastric cancer; GEJC, gastroesophageal junction carcinoma; HCC, hepatocellular carcinoma; LA, locally advanced; NPC, nasopharyngeal carcinoma; NonSq, non-squamous; NSCLC, non-small cell lung cancer; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; Sq, squamous; TIGIT, T-cell immunoreceptor with Ig and ITIM domains; UBC, urothelial bladder cancer.

¹Ensem collaboration; BeiGene has global rights.

Product	Mechanism	Indication	Phase 1	Phase 2	Phase 3	Countries Where Registered
BGB-43395	CDK4 inhibitor	BC and solid tumors				
BG-C9074 ¹	B7H4 ADC	BC and solid tumors				
BGB-C354	B7H3 ADC	Solid tumors				
LBL-007 ²	anti-LAG3	MSS-CRC				
		1L ESCC				
Umbrella	IO combinations	1L NSCLC ^a				
		Neo/adj NSCLC ^a				
		2L+ NSCLC ^a				
		1L HNSCC ^a				
Zanidatamab ³	anti-HER2 BsAb	2L HER2+ BTC				
		1L HER2+ GEA				
BGB-A445	anti-OX40	Melanoma, UC				
BGB-15025	HPK1 inhibitor	Solid tumors				
BGB-26808	HPK1 inhibitor	Solid tumors				
BGB-24714	SMAC mimetic	Solid tumors				

Safety and efficacy have not been established for investigational products and/or uses.

Abbreviations: 1L, first line; 2L, second line; ADC, antibody-drug conjugate; BC, breast cancer; BsAb, bispecific antibody; BTC, biliary tract cancer; CDK4, cyclin-dependent kinase 4; CRC, colorectal cancer; ESCC, esophageal squamous cell carcinoma; GEA, gastroesophageal adenocarcinomas; HER2, human epidermal growth factor receptor 2; HNSCC, head and neck squamous cell carcinoma; HPK1, hematopoietic progenitor kinase 1; IO, immunotherapy; LAG3, lymphocyte activation gene 3; MSS, microsatellite stability; NSCLC, non-small cell lung cancer; OX40, a member of the tumor necrosis factor (TNF) receptor family, also known as CD134; PD-1, programmed cell death protein 1; SMAC, second mitochondria-derived activator of caspase; UC, urothelial carcinoma.

^aMay include anti-PD-1, anti-LAG3, anti-OX40, and HPK1 inhibitor.

¹DualityBio collaboration; BeiGene has global clinical, manufacturing, and commercialization rights.

²Leads Biolabs collaboration; BeiGene has global research, development, and manufacturing rights, and exclusive commercialization rights outside of China.

³Zymeworks/Jazz collaboration; BeiGene has exclusive development and commercialization rights in Asia (except Japan), Australia, and New Zealand.

Product	Mechanism	Indication	Phase 1	Phase 2	Phase 3	Countries Where Registered
BGB-30813	DGKζ inhibitor	Solid tumors				
BGB-A3055	anti-CCR8	Solid tumors				
Pamiparib	PARP 1/2 inhibitor	2L MTx gBRCAm PSOC				
Taratamab ¹	DLL3 x CD3	2L SCLC				
		1L-ES-SCLC				
		LS-SCLC				
		3L+ SCLC (initiation activities)				
Xaluritamig ¹	STEAP1 x CD3	mCRPC				
BGB-R046	IL-15 prodrug	Solid tumors				
BGB-B3227	MUC1 x CD16A BsAb	Lung and GI				
BGB-B2033	GPC3 x 4-1BB	Solid tumors				
BG-C477	CEA ADC	Lung and GI cancers (preclinical)	Planned for 2024			
BGB-53038	PanKRAS inhibitor	Lung and GI cancers (preclinical)	Planned for 2024			
BG-C137	FGFR2b ADC	GI cancer (preclinical)	Planned for 2024			
BGB-58067	PRMT5 inhibitor	Lung and GI cancers (preclinical)	Planned for 2024			
BG-60366	EGFR-targeted CDAC	Lung cancer (preclinical)	Planned for 2024			

Safety and efficacy have not been established for investigational products and/or uses.

Abbreviations: 1L, first line; 2L, second line; 3L, third line; 4-1BB, tumor necrosis factor receptor superfamily member 9; ADC, antibody-drug conjugate; BsAb, bispecific antibody; CCR8, the C-C motif chemokine receptor 8; CD16A, Fc receptor FcγRIIIa; CD3, cluster of differentiation 3; CDAC, chimeric degradation activating compound; CEA, carcinoembryonic antigen; DGKζ, diacylglycerol kinase ζ; DLL3, delta-like ligand 3; EGFR, epidermal growth factor receptor; ES-SCLC, extensive-stage small cell lung cancer; FGFR2b, fibroblast growth factor receptor 2, isoform IIIb; gBRCAm, germline BRCA1/2 mutation; GI, gastrointestinal; GPC3, glypican-3; IL-15, interleukin-15; KRAS, Kirsten rat sarcoma virus; LS-SCLC, limited-stage small cell lung cancer; mCRPC, metastatic castration-resistant prostate cancer; MTx, maintenance treatment; MUC1, mucin 1; PARP 1/2, poly (ADP-ribose) polymerase 1 and 2; PRMT5, protein arginine methyltransferase 5; PSOC, platinum-sensitive ovarian cancer; SCLC, small cell lung cancer; STEAP1, six-transmembrane epithelial antigen of the prostate 1.

¹Amgen collaboration; BeiGene has development and commercialization rights in China.